These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience. Guerra-García P; Bomken S; Ling R; Lazareva A; Gupte G; Amrolia P; Andrés M; Diez-Sebastián J; Taj MM Pediatr Blood Cancer; 2024 Aug; 71(8):e31053. PubMed ID: 38757407 [TBL] [Abstract][Full Text] [Related]
14. Stage IV Classical Hodgkin Lymphoma-type Posttransplant Lymphoproliferative Disorder in a Pediatric Liver Transplant Patient: A Case Report and Review of the Literature. Choi S; Hong KT; Choi JY; Ahn HY; Ko JS; Suh KS; Park SH; Cheon JE; Shin HY; Kang HJ J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1015-e1019. PubMed ID: 33769384 [TBL] [Abstract][Full Text] [Related]
16. Post-transplantation lymphoproliferative disorders localizing in the adenotonsillar region: report from the PTLD.Int survey. Khedmat H; Taheri S Ann Transplant; 2011; 16(1):109-16. PubMed ID: 21436784 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient. Basso S; Zecca M; Calafiore L; Rubert L; Fiocchi R; Paulli M; Quartuccio G; Guido I; Sebastiani R; Croci GA; Beschi C; Nardiello I; Ginevri F; Cugno C; Comoli P Pediatr Transplant; 2013 Nov; 17(7):E168-73. PubMed ID: 23992468 [TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations. Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399 [TBL] [Abstract][Full Text] [Related]
19. Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review. Zhou K; Gong D; Han Y; Huang W Ann Hematol; 2024 Jul; 103(7):2207-2213. PubMed ID: 37749317 [TBL] [Abstract][Full Text] [Related]
20. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]